The Effect of Growth Hormone-Secreting Pituitary Adenoma Disease Activity on Thyroid Nodules
Authors' conclusion
Chronic elevation of GH/IGF-1 levels in patients with GHPA is associated with the development and progression of thyroid nodules. Following treatment of GHPA, a reduction in GH/IGF-1 levels correlates with a decrease in thyroid nodule volume. Close monitoring of nodule growth and regular thyroid ultrasonography are recommended, particularly for nodules with malignant features.
Study context
- Population
- Patients with growth hormone-secreting pituitary adenoma (GHPA), medical records January 2009 to December 202454 with follow-up data
- Participants
- 150 patients
- Outcome
- Prevalence of thyroid nodules
Methodological detailslongitudinal follow-up
- Longitudinal follow-up
Main finding
As reported in the abstract
Prevalence of thyroid nodules in GHPA
74%
Observational data: associations, not effects.
Further findings
Correlates of baseline maximum thyroid nodule diameter (TND) and total thyroid nodule volume
- TND and total nodule volume positively correlated with age and IGF-1, negatively with TSH
- Patients with thyroid nodules had higher growth hormone (GH) levels
Change in TND during follow-up · baseline to last follow-up
- TND significantly decreased following marked reduction in GH/IGF-1
Risk factors for thyroid nodule occurrence (logistic regression)
- Baseline GH level an independent risk factor for thyroid nodules
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →